



**Press Release**

Monday, 03 Nov 2008

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

---

## **Strides Arcolab receives USFDA approval for one more product – Takes total Sterile product approvals to 12.**

---

Strides Arcolab Limited (“Strides”) today announced receipt of one ANDA approval for Pamidronate Disodium Injection, 3mg/ml (packaged in 30mg/10ml) and 9mg/ml (packaged in 90mg/10ml) Single use Vials.

The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn Inc [NASDAQ: AKRX] and Strides Arcolab Limited [NSE:STAR, BSE: 532531]

### **Ravi Seth, Chief Executive Officer- International Operations of Strides stated:**

“It is indeed gratifying that with 12 ANDA approvals, the Strides Akorn JV has a good sized offering of generic injectable products for the US markets. The JV which posted a healthy performance for Q3 2008, expects to have all these products launched in the market by Q1, 2009.”

### ***Strides Overview***

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral

dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides also has a collaboration agreement with Aspen Pharmacare involving a range of products and territories including a Joint Venture in the oncolytics space in Bangalore. Recently, the JV concluded a significant transaction with GSK to outlicense products for GSK's emerging market strategies in over 95 countries.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information about Strides is available at the company's website [www.stridesarco.com](http://www.stridesarco.com)

**For further information, please contact:**

Mr. Arun Kumar, Group CEO Tel: +91 80 6658 0118	Melissa Arulappan, Corporate Voice   Weber Shandwick Mob: +91 98450 22389 Email: <a href="mailto:Melissa@corvoshandwick.co.in">Melissa@corvoshandwick.co.in</a> ;
Mr. Ravi Seth, CEO International Operations Tel: +91 80 6658 0121	Merlin Francis, Corporate Voice   Weber Shandwick Mob: +91 98450 17375 Email: <a href="mailto:merlin@corvoshandwick.co.in">merlin@corvoshandwick.co.in</a> .